Trending...
- Governor Polis Celebrates Colorado StartUp Week, Encourages Next Generation of Entrepreneurs
- Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
- Notaron Expands Online Notarization Access Following Wisconsin Approval
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 million grant from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH). The grant supports clinical trials of their beta-amyloid vaccines based on DNA and recombinant protein for the prevention of Alzheimer's disease (AD). A phase 1 clinical study in the U.S. is expected to begin in second quarter 2022 and the vaccine will be exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.
Alzheimer's is a progressive brain disease that impacts 6.5 million Americans aged 65 and older. Moreover, currently 47 million people in the U.S. with asymptomatic preclinical Alzheimer's disease are off the radar of the pharmaceutical industry. There are several drugs and vaccines in the clinical development that have shown limited clinical results in the fight against it. In 2022, the total national cost of caring for people living with Alzheimer's and other dementias is projected to reach $321 billion.1 Up until now, AD therapeutics have mostly focused on treating the underlying pathology after the disease has taken hold. But once pathology begins and neurons are damaged, it becomes impossible to stop the disease. Current data suggest that an immunogenic preventive vaccine could induce high levels of antibodies inhibiting aggregation of Aβ in cognitively unimpaired people at risk of AD and delaying the disease onset.
More on Colorado Desk
Chris Cappello, President and CEO, PharmaJet commented, "We are pleased to be partnering with IMM in this important clinical trial and adding Alzheimer's disease to our growing nucleic-acid-based R&D pipeline. Studies have demonstrated that delivery with the PharmaJet Tropis System has improved vaccine effectiveness."
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2022;18. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
About PharmaJet
PharmaJet's mission is to enable greater access to life improving pharmaceuticals. PharmaJet's Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
More on Colorado Desk
About IMM
The Institute for Molecular Medicine (IMM) is a non-profit organization created with the goal of understanding, preventing and curing chronic human diseases, including neurodegenerative disorders. Based in Orange County, California, IMM along with Nuravax, a biotechnology company licensed IMM's patented technology, is advancing MultiTEP, a universal vaccine platform technology that supports the development of multiple vaccine designs based on DNA, RNA, or recombinant proteins. For more information, please visit www.nuravax.com and follow us on LinkedIn.
Contacts
Nancy Lillie
Nancy.Lillie@pharmajet.com
1-888-900-4321 Option 3
Alzheimer's is a progressive brain disease that impacts 6.5 million Americans aged 65 and older. Moreover, currently 47 million people in the U.S. with asymptomatic preclinical Alzheimer's disease are off the radar of the pharmaceutical industry. There are several drugs and vaccines in the clinical development that have shown limited clinical results in the fight against it. In 2022, the total national cost of caring for people living with Alzheimer's and other dementias is projected to reach $321 billion.1 Up until now, AD therapeutics have mostly focused on treating the underlying pathology after the disease has taken hold. But once pathology begins and neurons are damaged, it becomes impossible to stop the disease. Current data suggest that an immunogenic preventive vaccine could induce high levels of antibodies inhibiting aggregation of Aβ in cognitively unimpaired people at risk of AD and delaying the disease onset.
More on Colorado Desk
- NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
- Regional Magazines Shine at IRMA Awards
- Following Federal Approval of Colorado's Major Disaster Declaration, FEMA Denies Individual Assistance and the Hazard Mitigation Grant Funding Portions of Original Request
- Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List
- Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
Chris Cappello, President and CEO, PharmaJet commented, "We are pleased to be partnering with IMM in this important clinical trial and adding Alzheimer's disease to our growing nucleic-acid-based R&D pipeline. Studies have demonstrated that delivery with the PharmaJet Tropis System has improved vaccine effectiveness."
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2022;18. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
About PharmaJet
PharmaJet's mission is to enable greater access to life improving pharmaceuticals. PharmaJet's Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
More on Colorado Desk
- Colorado Springs: CSPD investigation leads to arrest warrant; Detectives seek assistance locating suspect and potential additional victims
- Colorado's Economic Forecast Shows Growth Stable but Slowing
- Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
- More than $13M in New Funding Supports Conservation Stewardship for Colorado Farmers and Ranchers
- Colorado's Economic Forecast Shows Growth Stable but Slowing
About IMM
The Institute for Molecular Medicine (IMM) is a non-profit organization created with the goal of understanding, preventing and curing chronic human diseases, including neurodegenerative disorders. Based in Orange County, California, IMM along with Nuravax, a biotechnology company licensed IMM's patented technology, is advancing MultiTEP, a universal vaccine platform technology that supports the development of multiple vaccine designs based on DNA, RNA, or recombinant proteins. For more information, please visit www.nuravax.com and follow us on LinkedIn.
Contacts
Nancy Lillie
Nancy.Lillie@pharmajet.com
1-888-900-4321 Option 3
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Icon Dental Unveils Dedicated Invisalign® Denver Service Page for Whole-Health & TMJ Treatment
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- ImagiPortal Launches 3D Video Calls and Onchain IP Registration Ahead of Pre-Seed Funding Round
- Governor Polis Takes Executive Action to Protect and Support Colorado Pollinators
- FEMA Releases Funding for Public Assistance and Hazard Mitigation Grants for Colorado, Some Dating Back to 2013
- Andrew-Thomas Contractors Launches Enhanced Safety Bollards Resource for Denver Metro Businesses
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
- Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
- Most Indiana Plane Crashes Happen Away from the State's Major Airports
- L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
- Mom Era, Still That Girl: Family Art Tees 25% Off
- Fashion vs. Fascism - Because Democracy Should Always Be In Style
- Colorado: Governor Polis Appoints Jeffrey M. Schwartz to the 8th Judicial District Court and Michael M. Perez to the Weld County Court in the 19th Judicial District
- Mayor Yemi names Shawna Lippert as Colorado Springs' next Economic Development Officer
- Governor Polis Celebrates Colorado StartUp Week, Encourages Next Generation of Entrepreneurs
- Lt. Governor Dianne Primavera Highlights Colorado's Leadership in Clean Energy at Uplight Ribbon Cutting
- Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
- Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Boston Industrial Solutions Introduces Personalized Printing Training